In vitro assay and in vivo effect of artemisinin in Trypanosoma brucei brucei-infected Wistar rats

Abstract Background Control of the trypanosomosis has been targeted towards vector control or by the use of antitrypanosomal drugs such as diminazene aceturate and isometamidium with reports of toxicity and relapse following treatment. Hence, the need for continuous research for a safe, efficacious and less toxic drug. In previous studies, artemisinin has shown antitrypanosomal effects against Trypanosoma brucei rhodesiense and also against Trypanosoma brucei brucei (T. b. brucei) in vitro. This period of drug repurposing has led to scientists searching for ways of utilising artemisinin because of its reported multifunctionality and ability to mediate several targets that are important for different diseases. Purpose To evaluate the in vivo effects of artemisinin against T. b. brucei following the in vitro assay. Methods Previously to perform the in vivo assays, the in vitro effects of artemisinin on the T. b. brucei trypomastigotes growth were assessed. The in vivo effects were tested on Wistar rats at doses 5 mg/kg and 10 mg/kg, respectively. All Wistar rats were euthanised at the end of the experiment; kidney, lung, liver and brain samples were harvested and processed for histopathological examination. Results Complete cessation (p Conclusions In vitro, artemisinin produced a complete inhibition of T. b. brucei motility at 2 and 20 µg/µl. In vivo, artemisinin at 5 and 10 mg/kg prevented histoarchitecture damage of selected organs and caused an elevated haematological profile.